NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer
نویسندگان
چکیده
منابع مشابه
Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.
Drug resistance leads to chemotherapy failure and is responsible for the death of a great majority of patients with metastatic, late-stage ovarian cancer. The present study addressed whether changes in the chemotherapy dosing schedule affect the development, further worsening, or circumvention of drug resistance in chemosensitive and chemoresistant ovarian cancer. Severe combined immunodeficien...
متن کاملClinical resistance to platinum chemotherapy in ovarian cancer
Platinum drugs are the most active agents in ovarian cancer. Their cytotoxicty results from DNA crosslinking. High tumour response rates are seen, but 80 % of patients relapse. Major mechanisms of platinum resistance in patients remain to be established. We have studied DNA interstrand crosslinking and its repair in response to ex vivo treatment with cisplatin in forty patients with ovarian can...
متن کاملNew Strategy for Overcoming Resistance to Chemotherapy of Ovarian Cancer
BACKGROUND Ovarian cancer is one of the most sensitive solid tumors, with objective responses ranging from 60 to 80% even in patients with advanced stage. However, most patients ultimately recur and develop resistance to chemotherapy. As a result, the survival rate for patients with ovarian cancer has not improved over the past 20 years. Resistance to chemotherapy presents a major obstacle to a...
متن کاملChemotherapy-induced Ovarian Failure And The Related Indices In Breast Cancer Patients
Background and Objective: It is well known that menstrual period and ovarian function are affected by chemotherapy. Although breast cancer is the most common cause of chemotherapy in women and ovarian hormones have very important direct and indirect effects on overall survival, disease-free survival, and...
متن کاملNeoadjuvant Chemotherapy in Ovarian Cancer
Objective: The primary objective of the study was to compare the efficacy and safety of adjuvant chemotherapy (ACT) with neoadjuvant chemotherapy (NACT) in patients with ovarian epithelial cancer (OEC). Place & Duration of Study: This Randomized Controlled Trial was conducted at Shaukat Khanum Memorial Cancer Hospital & Research Center, Lahore (Pakistan). Patients were enrolled and treated over...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JCI Insight
سال: 2020
ISSN: 2379-3708
DOI: 10.1172/jci.insight.131486